Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business UpdateMarch 31, 2022

Emmaus Life Sciences, Inc. today reported financial results for the year ended December 31, 2021 and an update on recent activities.

Emmaus Life Sciences Announces Endari To Be Added to the Florida Medicaid Preferred Drug ListMarch 29, 2022

Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for EndariMarch 23, 2022

Emmaus Life Sciences, Inc. today announced the approval of its application for marketing authorization of Endari® from the United Arab Emirates (U.A.E.) Ministry of Health after a five-month review of the company’s marketing authorization application.

Emmaus Life Sciences’ Real World Data on Endari Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for HaematologyMarch 04, 2022

Emmaus Life Sciences, Inc. today announced that real world data on Endari®, the company’s prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for an e-poster at the 62nd Annual Meeting of the British Society for Haematology (BSH) to be held April 3 -5, 2022 at the Manchester Central in Manchester, England and virtually.

Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect ConferenceJanuary 04, 2022

Emmaus Life Sciences, Inc. today announced that Yutaka Niihara, M.D., M.P.H, Chairman and Chief Executive Officer of Emmaus, will present a company overview at the H.C. Wainwright BioConnect Conference, being held virtually, January 10-13, 2022